v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash Flows From Operating Activities    
Net income $ 6,702 $ 1,954
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 300 1,026
Interest accretion expense 34 112
Amortization of deferred financing fees 42
Stock-based compensation 291 630
Amortization on operating lease right of use asset 448 575
Change in fair value of note payable 547 678
Change in fair value of contingent consideration 7
Other changes in operating assets and liabilities:    
Accounts receivable (3,466) 227
Other current assets 73 (89)
Accounts payable 120 489
Accrued salaries and bonus 238 513
Accrued liabilities (404) (2,266)
Operating lease liabilities (480) (376)
Long-term liabilities 243 267
Net cash provided by operating activities 4,646 3,789
Cash Flows From Investing Activity    
Proceeds from sale of Interpace Pharma Solutions, net 383
Purchase of property and equipment (876) (470)
Net cash used in investing activities (876) (87)
Cash Flows From Financing Activities    
Payments made on note payable (5,600)
Series C Preferred stock issuance costs (161)
Payment of BroadOak terminal payment (2,500)
Payments on line of credit (2,500)
Cash paid for repurchase of restricted shares (46) (32)
Net cash used in financing activities (5,807) (5,032)
Net decrease in cash and cash equivalents (2,037) (1,330)
Cash and cash equivalents from continuing operations – beginning 3,498 4,828
Cash and cash equivalents from discontinued operations – beginning
Cash and cash equivalents  – beginning 3,498 4,828
Cash and cash equivalents from continuing operations – ending 1,461 3,498
Cash and cash equivalents from discontinued operations – ending
Cash and cash equivalents  – ending $ 1,461 $ 3,498

Source